Portal de Periódicos da CAPES

Overview of the current use of levosimendan in France: a prospective observational cohort study

2023; Springer Nature; Volume: 13; Issue: 1 Linguagem: Inglês

10.1186/s13613-023-01164-3

2110-5820

Bernard Cholley, Mirela Bojan, B. Guillon, Emmanuel Besnier, Mathieu Mattèi, Bruno Lévy, Alexandre Ouattara, Nadir Tafer, Clément Delmas, David Tonon, Bertrand Rozec, Jean-Luc Fellahi, Pascal Lim, François Labaste, François Roubille, Thibaut Caruba, Philippe Mauriat, Olivier Barbot, Berthomieu Laurent, Anne-Marie Besselat, Blanchart Katrien, Adrien Bouglé, Pierre Bourgoin, Causeret Arnaud, Hélène Charbonneau, Mircea Cristinar, Olivier Desebbe, Veldat Eljezi, Thibaud Genet, Maxime Grenier, Pierre-Grégoire Guinot, Stéphane Lebel, Yaël Levy, F. Lion, Jacques Mansourati, Stéphanie Marlière, Anne‐Céline Martin, Alexandre Mebazaa, Usman Mohammad, Jacques Monségu, Nicolas Nessler, Isabelle Orsel, Étienne Puymirat, Morgan Recher, Sabri Soussi, Vincent Troussard, Sabrina Uhry, Xavier Zirphile,

Cardiovascular Syncope and Autonomic Disorders

Following the results of randomized controlled trials on levosimendan, French health authorities requested an update of the current use and side-effects of this medication on a national scale.The France-LEVO registry was a prospective observational cohort study reflecting the indications, dosing regimens, and side-effects of levosimendan, as well as patient outcomes over a year.The patients included (n = 602) represented 29.6% of the national yearly use of levosimendan in France. They were treated for cardiogenic shock (n = 250, 41.5%), decompensated heart failure (n = 127, 21.1%), cardiac surgery-related low cardiac output prophylaxis and/or treatment (n = 86, 14.3%), and weaning from veno-arterial extracorporeal membrane oxygenation (n = 82, 13.6%). They received 0.18 ± 0.07 µg/kg/min levosimendan over 26 ± 8 h. An initial bolus was administered in 45 patients (7.5%), 103 (17.1%) received repeated infusions, and 461 (76.6%) received inotropes and or vasoactive agents concomitantly. Hypotension was reported in 218 patients (36.2%), atrial fibrillation in 85 (14.1%), and serious adverse events in 17 (2.8%). 136 patients (22.6%) died in hospital, and 26 (4.3%) during the 90-day follow-up.We observed that levosimendan was used in accordance with recent recommendations by French physicians. Hypotension and atrial fibrillation remained the most frequent side-effects, while serious adverse event potentially attributable to levosimendan were infrequent. The results suggest that this medication was safe and potentially associated with some benefit in the population studied.